MedTrace Logo

A Study of NIDO-361 in Patients With SBMA

NCT06411912 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).

Conditions

  • Spinal and Bulbar Muscular Atrophy
  • Kennedy's Disease

Interventions

DRUG

NIDO-361

Tablets containing 100mg of NIDO-361 for oral administration.

DRUG

Placebo

Placebo oral tablets

Sponsors & Collaborators

  • Nido Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2025-10-22
Completion
2025-10-22

Countries

  • Denmark
  • Italy
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06411912 on ClinicalTrials.gov